Overview
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)
Status:
Completed
Completed
Trial end date:
2009-03-15
2009-03-15
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
The objective of this trial was to evaluate whether Corifollitropin Alfa treatment for the induction of multifollicular growth in women undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) was safe for pregnant participants and their offspring. The primary endpoint was the take-home baby rate calculated as the number of participants with an ongoing pregnancy in Base Trial P05787 (NCT00696800) with at least one live born infant relative to the number of participants in the Base Trial, and to the number of participants in the Base Trial with Embryo Transfer (ET).Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Follicle Stimulating Hormone
Ganirelix
Progesterone
Criteria
Inclusion Criteria:- Participants who received at least one dose of either Corifollitropin Alfa or
Puregon®/Follistim® AQ Cartridge in Base Trial P05787 (NCT00696800);
- Ongoing pregnancy confirmed by ultrasound at least 10 weeks after embryo transfer in
Base Trial P05787 (NCT00696800);
- Able and willing to give written informed consent.
Exclusion Criteria:
- None